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Four-Year Recurrence Rate and
Prognosis of the Apical Ballooning Syndrome
Ahmad A. Elesber, MD,* Abhiram Prasad, MD, FACC,* Ryan J. Lennon, MS,†
R. Scott Wright, MD, FACC, FESC,* Amir Lerman, MD, FACC,* Charanjit S. Rihal, MD, FACC*
Rochester, Minnesota
Objectives This study sought to assess the long-term prognosis of patients with apical ballooning syndrome (ABS).
Background Apical ballooning syndrome is a recently described acute cardiac syndrome of uncertain etiology and prognosis.
Methods We retrospectively identified 100 unselected patients with a confirmed diagnosis of ABS by angiography. Recur-
rences of ABS and mortality were recorded.
Results Over a mean follow-up of 4.4  4.6 years, 31 patients continued to have episodes of chest pain and 10 patients
had recurrence of ABS, for a recurrence rate of 11.4% over the first 4 years. Seventeen patients died in 4.7 
4.8 years of follow-up. There was no difference in survival or in cardiovascular survival to an age- and gender-
matched population.
Conclusions The recurrence rate for ABS was 11.4% over 4 years after initial presentation. Recurrence of chest pain is com-
mon. Four-year survival was not different from that in an age-matched and gender-matched population. (J Am
Coll Cardiol 2007;50:448–52) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.03.050d
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apical ballooning syndrome (ABS) is a recently described
cute cardiac syndrome (1). Several series have described the
linical features of the syndrome (2–8). Some reports have
escribed recurrence of ABS (3–6), and a few reports have
escribed the short-term prognosis (5,6). However, most of
hese series were small cohort studies (2–4,6,7) and none
eported the recurrence rate and the long-term prognosis
f ABS.
The goal of the current study was to assess the recurrence
ate of ABS after initial presentation and the factors
ssociated with ABS recurrence, and the long-term survival
f patients with ABS and identification of factors that
nfluence survival with ABS.
ethods
atients. This study was approved by the Mayo Founda-
ion Institutional Review Board. We searched the Mayo
ardiac Catheterization Laboratory database from January
988 through November 2005 for patients who underwent
oth coronary and left ventricular angiography and met the
reviously described Mayo Clinic criteria for ABS (1). Our
nitial search was restricted to patients with coronary artery
rom the *Division of Cardiovascular Diseases and the †Division of Biostatistics,
ayo Clinic, Rochester, Minnesota.c
Manuscript received January 8, 2007; revised manuscript received March 12, 2007,
ccepted March 19, 2007.iameter stenoses30% and apical hypokinesis, akinesis, or
yskinesis with sparing of the basal segments. This search
ielded 545 potential patients; 421 were excluded for other
ardiac diagnoses. Of the remaining 124 patients, 102 met
he criteria for the clinical identification of ABS (1). Two of
hese could not be contacted on follow-up. Thus, 100
atients comprised the study population.
The complete medical record and angiographic studies of
ach patient were reviewed. An ST-segment elevation was
efined as deviation 1 mm in amplitude in more than 2
ontiguous leads, and deep T-wave inversion was defined as
nversions 3 mm in amplitude in at least 3 contiguous
eads. All other electrocardiographic (ECG) changes that
id not fulfill these criteria were grouped under nonspecific
T/T-wave changes.
A measurement of left ventricular ejection fraction by
chocardiography was done according to the Simpson rule
9). Angiography was performed at presentation in 81
atients, on the second day in 12 patients, on the third day
n 5 patients, and on the fourth day in 2 patients. A
easurement of left ventricular ejection fraction by biplanar
ontrast left ventriculography was carried out by the mono-
lane area-length method (10).
linical follow-up. Follow-up data were collected through
etailed review of all medical records. Mailed questionnaires
nd telephone interviews with patients also were used to
omplete follow-up. For a diagnosis of recurrence, the
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July 31, 2007:448–52 4-Year Prognosis of Apical Ballooning Syndromeroposed Mayo criteria for the clinical diagnosis of ABS had
o be met with repeat coronary angiography (1). The cause
f death was confirmed by review of all available clinical
nformation at the time of death and by review of death
ertificates.
tatistical analysis. Continuous data are summarized as
ean  SD unless otherwise noted. Frequencies and
ercentages are used to describe discrete variables. Kaplan-
eier methods were used to estimate long-term survival. A
atient Clinical Characteristics
Table 1 Patient Clinical Characteristics
Total Population
n 100
Age  SD, yrs 66  13
Female (%) 95 (95%)
Hypertension (%) 52 (52%)
Diabetes mellitus (%) 5 (5%)
Hyperlipidemia (%) 33 (33%)
Tobacco use
Never (%) 62 (62%)
Past (%) 20 (20%)
Current (%) 18 (18%)
Presentation
Chest pain (%) 77 (77%)
Dyspnea (%) 8 (8%)
Other (%) 15 (15%)
Days of hospitalization, median (25th, 75th
interquartile)
5 (4, 8)
Congestive heart failure at presentation (%) 44 (44%)
Intubation (%) 10 (10%)
IABP insertion 7 (7%)
Electrocardiography
ST-segment elevation* (%) 33 (33%)
Deep T-wave inversion† (%) 31 (31%)
Nonspecific ST\T-wave  (%) 33 (32%)
Left bundle branch block (%) 3 (3%)
Atrial fibrillation (%) 6 (6%)
Maximal QTc‡  SD, ms 513  65
Cardiac angiogram
Ejection fraction  SD, % 46  14
LVEDP  SD, mm Hg 23  8
Initial ejection fraction  SD, %
(by echocardiography) (n  57)
40  13
Follow-up ejection fraction  SD, %
(by echocardiography)
61  7
Maximal creatinine  SD, mg/dl 1.1  0.4
Troponin T, ng/ml, median (25th, 75th interquartile)
(n  47)
0.5 (0.2, 1.0)
Discharge medication
Beta-blockers (%) 56 (56%)
ACEi/ARB (%) 51 (51%)
Aspirin (%) 74 (74%)
Statins (%) 32 (32%)
nless otherwise specified, the data were available on all patients. *ST-segment elevation had an
nterior or anterolateral distribution in 26 of the 33 patients with ST-segment elevation (79%), was
iffuse in 5 cases (15%), and was inferior or lateral in 2 cases (6%). †With anterior or anterolateral
istribution in 16 of the cases, diffuse in 10 cases, and inferior or lateral in 5 cases. ‡71 patients
ad a prolonged corrected QT interval on electrocardiogram (460 ms).
ACEi angiotensin-converting enzyme inhibitors; ARB angiotensin receptor blockers; IABPa
ntra-aortic balloon pump insertion; LVEDP  left ventricular end-diastolic pressure; QTc 
orrected QT interval.oisson model was used to esti-
ate 95% confidence intervals
or event rates per person-year.
he incidence of recurrence of
BS over time was estimated in
competing risks scenario, with
eath as the competing event
11). Simple hazard ratios for
ollow-up mortality were com-
uted using Cox proportional hazards models.
The risk of mortality (total and cardiac) observed in our
tudy cohort was compared with modeling of the expected
isk of mortality using data derived by applying age-,
ender-, and birth-year–specific mortality rates from the
innesota white population (12,13) to the age-, gender-,
nd birth-year–specific person-years of follow-up in this
ohort. Population rates were not available after the year
002, so 2002 rates were carried forward for subsequent
ears. One-sample log-rank tests were used to compare the
bserved and expected cardiac event rates (14).
esults
linical characteristics. Clinical characteristics for the en-
ire cohort are summarized in Table 1. All 100 study
atients were white. Most patients were local residents, with
6 patients living within a 60-mile radius of the hospital,
nd 92 within a 120-mile radius. Troponin T levels were
vailable for 47 patients and showed elevation in all but 1
atient. A summary of identifiable precipitating events for
he ABS is provided in Table 2.
resentation and hospital outcome. The most common
resentation of patients with ABS was the combination of
hest pain, ECG abnormalities, and a mild elevation in
ardiac biomarkers.
The left ventricular ejection fraction was depressed at
resentation in all patients, with normalization at a median
f 69 days from presentation (interquartile range 27 to 348
ays). Coronary angiography at initial evaluation indicated a
ormal left anterior descending artery in 41 patients and
ild stenoses (30%) in 59 patients.
During the index hospitalization, 6 patients had life-
hreatening arrhythmias: 1 patient presented with a ventric-
lar fibrillation arrest; 1 patient presented with ventricular
achycardia and cardiac arrest; 2 patients presented with
econd-degree atrioventricular block, 1 of whom subse-
uently required permanent pacemaker implantation; and 2
atients had asystolic arrest during hospitalization. Two
atients died during index hospitalization, both after a
ardiac arrest, 1 with ventricular fibrillation and 1 with
systole.
Discharge medications are listed in Table 1. When the
opulation was stratified according to year of presentation
1988 to 1993 vs. 1994 to 1999 vs. 2000 to 2005), use of
eta-blockers (17% vs. 44% vs. 74%, p  0.001),
Abbreviations
and Acronyms
ABS  apical ballooning
syndrome
ECG 
electrocardiographic/
electrocardiographyngiotensin-converting enzyme inhibitors/angiotensin re-
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4-Year Prognosis of Apical Ballooning Syndrome July 31, 2007:448–52eptor blockers (17% vs. 36% vs. 64%, p  0.001), and
tatins (6% vs. 28% vs. 42%, p  0.01) increased signifi-
antly, whereas the use of aspirin did not change (83% vs.
4% vs. 75%, p  0.34).
vents occurring during follow-up. Follow-up informa-
ion was available for all 100 patients. Most patients were
ocal residents and subsequently returned to Mayo Clinic for
heir general medical care. The frequency of returns was
ariable. Data from multiple return visits were available for
4 patients. The other 16 patients were sent questionnaires
nd contacted by telephone if no response was received.
ecurrence of ABS. The ABS recurred in 10 patients over
mean follow-up of 4.4  4.6 years. Figure 1 shows the
aplan-Meier estimated rate of ABS recurrence. The re-
urrence rate was highest within the first 4 years at about
.9% per year, subsequently decreasing to about 1.3% per
ear over the remainder of follow-up. The relatively small
umber of patients and recurrences did not allow meaning-
ul statistical analysis of factors predicting the recurrence
f ABS.
Of note, only 2 patients had an identifiable precipitating
vent at recurrence (pneumothorax in 1 and significant
oney loss at the casino in another). The ejection fraction
as 38  16%. One patient died at recurrence secondary to
entricular fibrillation arrest.
Medical therapy at the time of last follow-up was not
ifferent from that started at the index evaluation for any
reatment studied (data not shown). At the time of recur-
ence of ABS, there was no difference between the patients
ho did and did not have recurrence in the use of aspirin
recipitating Factors
Table 2 Precipitating Factors
Identifiable Precipitating Factors
Emotional stressor 26
Death of a family member 8
Severe argument 5
New diagnosis of personal disease 4
Involvement in a minor car accident 3
Public speech 2
Daughter’s divorce 1
Dog caught in a raccoon trap 1
New diagnosis of a disease in a family member 1
Move to a new residence 1
Casino loss 1, at recurrence
Physical stressor 30
Noncardiac surgery or procedure 12
Severe illness 5
Fracture 4
Asthma/COPD exacerbation 4
Stroke/transient ischemic attack 2
Pneumothorax 1
Pulmonary embolism 1
Renal colic 1
No identifiable stressor 44
OPD  chronic obstructive pulmonary disease.60% vs. 67%, p  0.67), angiotensin-converting enzymenhibitors/angiotensin receptor blockers (60% vs. 51%, p 
.59), beta-blockers (80% vs. 52%, p  0.10), and statins
40% vs. 33%, p  0.67).
orbidity. A total of 31 patients continued to experience
pisodes of chest pain. Of these 31 patients, 12 had chest
ain resulting in at least 1 hospital admission, with 3 having
epeat coronary angiography showing nonobstructive coro-
ary atherosclerosis. Two patients had progression to severe
ongestive heart failure requiring in-patient treatment (in 1
ase, repeat echocardiography showed normal ejection frac-
ion). Only 1 patient (male) had progression of coronary
therosclerosis requiring bypass surgery more than 16 years
fter the index presentation.
ortality. Seventeen patients died over a mean follow-up
f 4.7  4.8 years. Table 3 summarizes the causes of death.
able 4 summarizes univariate models for predictors of
eath after ABS index presentation. Multivariate analysis
as not possible because of the small number of events.
Figure 2 shows the survival estimates of the population, as
ell as the expected survival for an age-, gender-, birth
ear-, and race-matched population. Mortality did not differ
ignificantly between our study population and the matched
ontrol population. Figure 3 shows the cardiovascular sur-
ival estimates of the population, as well as the expected
ardiovascular survival for an age-, gender-, birth year-, and
ace-matched population. Cardiovascular mortality did not
iffer significantly between our study population and the
atched control population.
iscussion
his series of 100 patients with ABS clarifies important
ssues related to the natural history of ABS. First, recurrence
f ABS is infrequent. Second, 4-year survival of patients
Figure 1 Recurrent Rate of ABS
Kaplan-Meier curve showing recurrence of apical ballooning syndrome (ABS)
over time for the total patient population. Number of patients still at risk is
noted at 2-year intervals below the time axis.
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July 31, 2007:448–52 4-Year Prognosis of Apical Ballooning Syndromeith ABS is similar to the expected survival for an age-,
ender-, birth year-, and race-matched population.
Patients with ABS have a presentation similar to that for
n acute coronary syndrome. Despite the considerable
orbidity with which these patients present, most patients
urvive the index hospitalization with adequate medical
upport. In the present report, in-hospital mortality was low
2%) and generally caused by a cardiac arrhythmia. These
ndings compare favorably with the reported rates of
n-hospital mortality of 9% to 10% in nonselected case series
f myocardial infarction (15,16).
auses of Death
Table 3 Causes of Death
Causes of Death
Arrhythmia 5
Aortic stenosis* 1
Lower-extremity arterial embolism 1
Malignancy 7
Lung cancer 1
Colon cancer 1
Leukemia 1
Bladder cancer 1
Breast cancer 2
Lymphoma 1
COPD 3
AML 1
Death from aortic stenosis occurred 16 years after index presentation with apical ballooning
yndrome, at which time no significant aortic stenosis was detected.
AML  amyotrophic lateral sclerosis; COPD  chronic obstructive pulmonary disease.
nivariate Analysis for Predictorsf Death After ABS Index Presentation
Table 4 Univariate Analysis for Predictorsof Death After ABS Index Presentation
Variable
Hazard
Ratio
Lower
Value
Upper
Value p Value
Male 0.91 0.12 6.91 0.93
Age (per decade) 1.49 0.97 2.29 0.069
Hypertension 0.53 0.20 1.43 0.21
Hyperlipidemia 0.85 0.30 2.42 0.76
Ever smoked 0.90 0.33 2.44 0.83
Initial ejection fraction at
angiography (per 10%)
0.64 0.44 0.94 0.023
LVEDP (per 10 mm Hg) 1.02 0.57 1.82 0.96
Congestive heart failure 1.36 0.53 3.55 0.52
Intubation 10.1 2.77 36.7 0.001
Log2 troponin 1.18 0.66 2.10 0.58
Log2 creatinine 1.67 0.57 4.91 0.35
Electrocardiography results* 0.44
Nonspecific ST/T segment 1.00 — —
ST-segment elevation 2.12 0.67 6.75 0.20
Deep T-wave inversion 1.47 0.42 5.14 0.55
Maximal QTc (per 50 ms) 1.18 0.79 1.79 0.41
Beta-blockers at discharge 0.80 0.28 2.29 0.68
ACEi/ARB at discharge 1.28 0.46 3.52 0.64
Aspirin at discharge 0.68 0.24 1.96 0.47
Statins at discharge 0.43 0.10 1.95 0.27Excluding the 3 patients with left bundle branch block, in whom there were no follow-up deaths.
ABS  apical ballooning syndrome; other abbreviations as in Table 1.The recurrence of ABS is infrequent: an average yearly
ecurrence rate of 2.9% over the first few years after the first
vent, subsequently decreasing to 1.3% per year over the
emainder of follow-up. The relatively small number of
ecurrences unfortunately precluded further analyses of pre-
ictors and outcomes. Although ABS is associated with a
yperadrenergic state (8), beta-blockade did not fully pre-
ent recurrences.
We report 4-year morbidity associated with ABS. Almost
ne-third of the patients continued to have episodes of chest
ain, and up to one-third of these patients required admis-
Figure 2 Survival of Patients With ABS Versus an
Age- and Gender-Matched Population
Kaplan-Meier curves showing estimated survival over time. Expected survival of
an age- and gender-matched population (expected) is shown along with survival
of patients with apical ballooning syndrome.
Figure 3 Cardiovascular Survival of Patients With ABS
Versus an Age- and Gender-Matched Population
Kaplan-Meier curves showing estimated cardiovascular survival over time.
Expected cardiovascular survival of an age- and gender-matched population
(expected) is shown along with cardiovascular survival of patients with apical
ballooning syndrome.
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4-Year Prognosis of Apical Ballooning Syndrome July 31, 2007:448–52ion for evaluation and management of chest pain (1). In
hose patients who had repeat coronary angiography, the
tudy showed no progression of atherosclerosis, highlighting
he difference in the pathophysiology between chest pain in
atients with ABS and patients with typical angina second-
ry to atherosclerotic heart disease.
Previous reports have commented only on the short-term
urvival of patients with ABS (3,5,6). In our study, patients
ith ABS had similar 4-year survival and cardiovascular
urvival to an age- and gender-matched population. The
-year prognosis of patients with ABS remains excellent,
aralleling the general clinical course of quick symptom
esolution.
In our case series, we observed no prognostic value of
roponin or B-type natriuretic peptide levels, and the ECG
ndings at index hospitalization did not predict short-term
r long-term survival. These features continue to distinguish
BS from acute coronary syndromes.
tudy limitations. The present study consists of a relatively
mall cohort of retrospectively identified patients with a rare
ondition that mimics acute coronary syndrome. Limita-
ions in our analysis include the small number of hard end
oints, which limits the analysis and the conclusions that
an be drawn from this analysis. Treatment of the patients
as empirical and may reflect treatment biases for which we
annot account or adjust fully. Other limitations include the
ack of systematic measurements of neurohormones and
ardiac enzymes; the maximal troponin T value was avail-
ble in only 47 patients beginning in 2001, although all
atients had at least 1 cardiac enzyme set available.
onclusions
ata from our case series of ABS cases suggest that
ecurrence is infrequent. The 4-year prognosis of patients
ith ABS was similar to that expected in an age- and
ender-matched population.
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